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Abstract 
Previously, we showed that chronic testosterone administration increased body weight 
(BW) and food intake (FI), but did not alter fat weight, in young female rats. To examine 
our hypothesis that the effects of androgens on BW, FI and body composition might be 
age-dependent, the effects of chronic testosterone administration were evaluated in rats 
of different ages; i.e., young and middle-aged rats. Although chronic testosterone 
administration increased BW gain, FI, and feed efficiency in both young and middle-aged 
rats, it increased visceral fat weight in middle-aged rats, but not in young rats. Therefore, 
it is possible that testosterone promotes the conversion of energy to adipose tissue and 
exacerbates fat accumulation in older individuals. In addition, although the administration 
of testosterone increased the serum leptin level, it did not alter hypothalamic neuropeptide 
Y mRNA expression in middle-aged rats. On the contrary, the administration of 
testosterone did not affect the serum leptin levels of young rats. Thus, testosterone might 
induce hypothalamic leptin resistance, which could lead to fat accumulation in older 
individuals. Testosterone might disrupt the mechanisms that protect against adiposity and 
hyperphagia and represent a risk factor for excessive body weight and obesity, especially 
in older females. 
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Introduction 
    Energy balance and reproduction are closely linked in most species. The sex 
hormones, estrogen and androgens, are involved in the regulation of food intake (FI), 
body weight (BW), body composition, and energy metabolism in mammals and humans 
[1]. In females, estrogen plays pivotal roles in preventing excess BW gain and adiposity 
by suppressing FI and increasing energy metabolism. For example, ovariectomy increases 
FI and BW in female mammals, and these effects can be prevented by estradiol (E2) 
replacement [2]. Some of estrogen’s effects are mediated by estrogen receptor-α (ER-α) 
in the hypothalamus and brainstem, and the injection of E2 into the hypothalamic 
paraventricular nucleus decreased BW and FI in ovariectomized (OVX) rats [3,4]. 
However, as most of these studies involved young animals it remains unclear whether 
older animals continue to be responsive to the nutritional and metabolic effects of 
estrogen. Recently, Santollo et al. have shown that young and middle-aged female rats 
exhibit similar sensitivity to the anorexigenic effects of E2, suggesting that the response 
to estrogen is maintained in older individuals [5]. 
    On the other hand, the roles of androgens in female FI and BW regulation have not 
been fully examined, although some studies have shown that androgens increase FI and 
BW in females [1,6-8] and raise the risk of visceral obesity in women and experimental 
animals [9-13]. In our previous study, we evaluated the effects of chronic testosterone 
administration on BW, FI, and body composition in young female rats [14]. As a result, 
we found that BW gain and FI were increased by chronic testosterone administration, but 
the weights of visceral and subcutaneous fat were not changed. Interestingly, BW gain, 
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FI, and fat weight were not altered by chronic testosterone administration in OVX rats in 
the latter study. Therefore, these findings indicate that, similar to the actions of estrogen, 
the effects of androgens on BW, FI, and body composition might differ in an age-
dependent manner. 
    To further investigate this hypothesis, we evaluated the effects of the chronic 
administration of testosterone in different age groups; i.e., young and middle-aged rats, 
in the present study. The effects of chronic testosterone administration on BW, FI, and 
visceral and subcutaneous fat accumulation were assessed. In addition, the levels of 
neuropeptide Y (NPY) and prepro-orexin (pp-orexin), which are peripheral and 
hypothalamic orexigenic factors, respectively, and leptin, proopiomelanocortin (POMC), 
and the leptin receptor (OBRb), which are anorexigenic factors, were also investigated 
because it has been reported that sex steroids affect the serum and hypothalamic levels 
and actions of these factors [15-18]. The hypothalamic mRNA expression level of the 
androgen receptor (AR) was also measured because the AR plays pivotal roles in the 
regulation of BW and FI [1]. 
 
Experimental 
Animals 
Eighteen young (10 weeks of age) and 16 middle-aged (12 months of age) Sprague-
Dawley female rats (Charles River, Kanagawa, Japan) were housed in a room under 
controlled lighting (12 h light, 12 h darkness; lights turned on at 0800 and turned off at 
2000) and temperature (24°C) conditions with free access to food and water. All animal 
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experiments were conducted in accordance with the ethical standards of the institutional 
animal care and use committee of the University of Tokushima. Rats were randomly 
assigned to either the testosterone-administered (T) or the no testosterone (control) group 
(n = 8 or 9 per group). In the testosterone group, a silastic tube filled with crystalline 
testosterone was implanted into each rat (inner diameter: 3 mm, outer diameter: 5 mm, 
length of the filled part: 30 mm) (As One Co., Ltd., Tokyo, Japan) (De Vries et al., 1994). 
In the control group, an empty tube was implanted into each rat. BW and cumulative FI 
were assessed every week, and the rats were sacrificed by decapitation at 4 weeks (wk) 
after the implantation procedure. The implantation and decapitation were carried out 
under sevoflurane anesthesia. The brain, blood, visceral fat (parametrial, perirenal, and 
mesenteric deposits), and subcutaneous fat (inguinal deposits) were collected. The 
weights of visceral and subcutaneous fat were assessed immediately after removal, and 
samples (around 300-400 mm3) of visceral (parametrial) fat were dissected. The serum 
was separated by centrifugation and stored at –20°C, and the tissue samples were stored 
at −80°C. 
Hormone assay 
    Serum leptin levels were measured using radioimmunoassay kits (multi-species 
leptin RIA kit, Linco Research Inc., MO, USA). The sensitivity of the assay was 1.0 ng/ml, 
and its inter- and intra-assay coefficients of variation were 3.2% and 7.8%, respectively. 
Serum estradiol (E2) levels were measured by a commercial laboratory (SRL, Tokyo, 
Japan.) using a chemiluminescence immunoassay. Detection limit of E2 kit is 10 pg/mL 
and co-efficient of variations is smaller than 7%. 
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Quantitative real-time polymerase chain reaction 
    Whole hypothalamic explants were dissected from the frozen brains, as described 
previously [14]. Briefly, the brain sections were dissected out via an anterior coronal cut 
at the posterior border of the mammillary bodies, parasagittal cuts along the hypothalamic 
fissures, and a dorsal cut 2.5 mm from the ventral surface. Total RNA was isolated from 
the hypothalamic explants and visceral fat using a TRIzol® reagent kit (Invitrogen Co., 
Carlsbad, CA, USA) and an RNeasy® mini kit (Qiagen Gmbh, Hilden, Germany). Then, 
cDNA was synthesized with oligo (deoxythymidine) primers at 50°C using the 
SuperScript III first-strand synthesis system for the real-time polymerase chain reaction 
(PCR; Invitrogen Co.). The PCR analysis was performed using the StepOnePlusTM real-
time PCR system (PE Applied Biosystems, Foster City, CA, USA) and FAST SYBR® 
green. The hypothalamic mRNA levels of OBRb, the AR, NPY, POMC, and pp-orexin 
and the leptin mRNA level in visceral fat were measured. The mRNA expression level of 
each factor was normalized to that of GAPDH or the 18S rRNA level. Dissociation curve 
analysis was also performed for each gene at the end of the PCR. Each amplicon 
generated a single peak. The relevant primer sequences, product sizes, and annealing 
temperatures are shown in Table 1. The PCR conditions were as follows: initial 
denaturation and enzyme activation were carried out at 95°C for 20 s, followed by 45 
cycles of denaturation at 95°C for 3 s, and annealing and extension for 30 s. 
Statistical analysis 
All results are presented as mean ± SEM values. Two-way repeated or factorial ANOVA 
was used to compare the effects of testosterone between young and middle-aged rats. 
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Tukey-Kramer post-hoc analysis was used to determine individual group differences 
following the detection of significant main or ANOVA effects (P <0.05). 
 
Results 
    At the beginning of the study, the mean BW of the young groups were significantly 
lower than those of the middle-aged groups (young-control: 222.7 ± 3.1 g, young-T: 221.3 
± 3.3 g, middle-control: 423.7 ± 12.2 g, middle-T: 426.3 ± 8.8 g). At 4 wk after the 
implantation procedure, the serum E2 levels of the examined groups did not differ 
(young-control: 32.4 ± 3.2 pg/mL, young-T: 32.9 ± 3.6 g, middle-control: 42.4 ± 6.2 g, 
middle-T: 28.3 ± 6.8 g). 
    Repeated-measures ANOVA revealed a significant interactive effect of treatment × 
time on the change in BW (F = 69.3, P <0.01) (Fig. 1A). Both T (F = 58.0, P <0.01) and 
age (F = 4.70, P <0.01) had significant effects on the BW change seen at 4 wk after the 
implantation procedure (Fig. 1B). Post-hoc analysis showed that the BW changes 
observed at 4 wk after the implantation procedure in the young-T and middle-T groups 
were significantly greater than those seen in the young-control and middle-control groups, 
respectively (Fig. 1B). It also showed that the BW changes observed at 4 wk after the 
implantation procedure in the young-control and young-T groups were significantly 
greater than those seen in the middle-control and middle-T groups, respectively. 
Repeated-measures ANOVA revealed a significant interactive effect of treatment × time 
on cumulative FI (F = 163.3, P <0.01) (Fig. 1C). Both T (F = 31.0, P <0.01) and age (F 
= 28.0, P <0.01) had significant effects on cumulative FI at 4 wk after the implantation 
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procedure (Fig. 1D). Post-hoc analysis showed that cumulative FI at 4 wk after the 
implantation procedure was significantly greater in the young-T and middle-T groups 
than in the young-control and middle-control groups, respectively (Fig. 1D). It also 
showed that the young-control and young-T groups exhibited significantly greater 
cumulative FI at 4 wk after the implantation procedure than the middle-control and 
middle-T groups, respectively. 
    Both T (F = 171.7, P <0.01) and age (F = 7.16, P <0.01) had significant effects on 
feed efficiency (FE). Post-hoc analysis showed that FE was significantly higher in the 
young-T and middle-T groups than in the young-control and middle-control groups, 
respectively (Fig. 2A). It also demonstrated that FE was significantly higher in the young-
control and young-T groups than in the middle-control and middle-T groups, respectively. 
Both T (visceral fat: F = 5.40, P=0.03; total fat: F = 6.13, P=0.02) and age (visceral fat: 
F = 5.82, P <0.01; total fat: F = 7.95, P <0.01) had significant effects on relative visceral 
fat weight and total fat weight. Post-hoc analysis showed that the relative visceral fat 
weight and total fat weight of the middle-T group were significantly heavier than those 
of the middle-control group (Figs. 2B and D). It also demonstrated that the relative 
visceral fat weight and total fat weight of the young-control and young-T groups were 
significantly lighter than those of the middle-control and middle-T groups, respectively. 
    Both T (F = 6.13, P <0.01) and age (F = 7.95, P <0.01) had significant effects on 
relative lean body mass. Post-hoc analysis showed that the relative lean body mass of the 
middle-T group was significantly lighter than that of the middle-control group (Fig. 2E). 
It also demonstrated that the relative lean body mass values of the young-control and 
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young-T groups were significantly heavier than those of the middle-control and middle-
T groups, respectively. 
    Both T (F = 11.8, P <0.01) and age (F = 7.64, P <0.01) had significant effects on the 
serum leptin level. Post-hoc analysis showed that the serum leptin levels of the middle-T 
group were significantly higher than those of the middle-control group (Fig. 3A). It also 
demonstrated that the serum leptin levels of the young-control and young-T groups were 
significantly lower than those of the middle-control and middle-T groups, respectively. 
Neither age nor T had significant effects on the leptin mRNA level in visceral fat (Fig. 
3B). Multiple comparisons tests showed that the visceral fat leptin mRNA levels of the 
young-control and young-T groups were significantly lower than those of the middle-
control and middle-T groups, respectively. 
    Age (F = 4.40, P <0.01), but not T (F = 4.38, P=0.05), had significant effects on the 
hypothalamic OBRb mRNA level. Post-hoc analysis showed that the hypothalamic 
OBRb mRNA level of the middle-control group was significantly higher than that of the 
young-control group (Fig. 4A). Neither age nor T had any effect on the mRNA levels of 
other hypothalamic factors (Figs. 4B-E). 
 
Discussion 
    As mentioned above, it has been shown that young and middle-aged female rats 
exhibit similar sensitivity to the anorexigenic effects of E2 and that older animals retain 
responsiveness to the nutritional and metabolic effects of estrogen [5]. On the other hand, 
although we have demonstrated that chronic testosterone administration promotes BW 
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gain and FI, but does not alter fat weight, in young female rats [14], it remains unclear 
whether these effects of testosterone vary according to age. In the present study, it was 
found that BW gain and FI were promoted by chronic testosterone administration in both 
young and middle-aged rats. In addition, FE was increased by testosterone administration 
in both groups, indicating that testosterone stimulates the conversion of energy to 
nutritional components. On the contrary, the effects of testosterone administration on 
body fat differed between young and middle-aged rats; i.e., it did not affect body fat 
accumulation in young rats, whereas it increased visceral fat weight in middle-aged rats. 
As well as the present findings, it has been reported that middle-aged (17 months) and 
old (31 months) rats exhibited significantly greater fat weights than young (4 months) 
rats [19]. Therefore, it is possible that testosterone administration promotes the 
conversion of energy to adipose tissue and exacerbates fat accumulation in older 
individuals. As far as we know, this is the first study to focus on the relationship between 
age and the effects of testosterone administration on BW, FI, and body composition. 
    In a previous study, we showed that the effects of chronic testosterone administration 
on BW and FI were abrogated in OVX rats, indicating that testosterone’s effects depend 
on the estrogen milieu [14]. As the serum E2 levels of the young and middle-aged rats in 
the present study did not differ, the discrepancies in the effects of testosterone 
administration seen between these groups might not have been caused by differences in 
the estrogen milieu. On the other hand, it is possible that testosterone-induced increase of 
adiposity could be attributed to estrogen antagonism by androgens acting on estrogens. 
To clarify the mechanism responsible for these intergroup differences, the levels of 
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peripheral and hypothalamic orexigenic/anorexigenic factors and the AR were evaluated 
because it has been reported that these factors mediate the effects of gonadal steroids on 
BW, FI, and energy metabolism [1,15-18] and that the effects of E2 administration on the 
gene expression levels of these factors change according to age [5]. As a result, it was 
found that the serum leptin level was increased by testosterone administration in middle-
aged rats, but not in young rats. In contrast, leptin mRNA expression was not affected by 
the administration of testosterone in either group, although the middle-aged rats displayed 
higher leptin mRNA expression than the young rats. Thus, the increase in the serum leptin 
level seen in the testosterone-treated middle-aged rats might have been due to greater fat 
deposition, rather than changes in leptin mRNA expression. It has been reported that 
leptin suppresses appetite and increases energy expenditure, and thereby, reduces FI and 
BW gain in non-obese conditions [20]. These effects of leptin on FI and BW are partially 
mediated by hypothalamic NPY; i.e., leptin downregulates hypothalamic NPY gene 
expression and suppresses appetite [21]. On the other hand, although obese humans and 
animals frequently exhibit elevated serum leptin levels [21,22], their hypothalamic 
sensitivity, including the sensitivity of NPY expression, to leptin are decreased, and this 
condition is called ‘leptin resistance’ [21]. Similarly, in the current study although the 
serum leptin level was increased by testosterone administration in the middle-aged rats, 
FI and BW gain were not suppressed, and the hypothalamic NPY mRNA expression level 
was not changed. In addition, the hypothalamic OBRb mRNA expression level was 
increased in the control middle-aged rats, which might be one of the counter-regulatory 
mechanisms that helps to prevent obesity, whereas no such changes in OBRb expression 
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were observed in the testosterone-treated middle-aged rats. Thus, it is possible that 
testosterone inhibits the mechanisms that protect against adiposity and obesity, and 
testosterone administration induced fat accumulation in middle-aged rats in the current 
study. On the other hand, we could not detect any testosterone-induced changes in the 
levels of other hypothalamic appetite regulatory factors; i.e., pp-orexin, POMC, and the 
AR. It has been reported that metabolic disturbances, such as obesity and insulin 
resistance, are predominant in older women with PCOS, which often associated with 
hyperandrogenism [23]. These results indicate that androgen might play important roles 
in the development of body weight gain and adiposity in older ages in women. Limitation 
of this study; because serum testosterone level in testosterone-administered groups were 
around 30-fold higher than that in control-groups (data not shown), indicating that the 
testosterone-administration induced supra-physiological testosterone levels in present 
study. Thus, another protocol, which induces lower testosterone level, would be needed 
to reproduce hyper-androgenic women. 
    There is one limitation in present study. Because serum estradiol levels were 
measured using chemiluminescence immunoassay, but not accurate methods such as 
LC/MS/MS, in this study, it is difficult to be sure whether changes in estradiol levels 
could be accurately detected between the groups. Therefore, further studies using more 
accurate measurement methods would be needed to clarify our hypothesis that 
testosterone’s effects on adiposity could be attributed to estrogen antagonism by 
androgens. 
    In summary, BW gain, FI, and FE were increased by chronic testosterone 
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administration in both young and middle-aged rats in the present study. These results 
indicate that testosterone stimulates the conversion of energy to nutritional components. 
Conversely, testosterone administration increased visceral fat weight in middle-aged rats, 
whereas it did not affect visceral fat weight in young rats. Therefore, testosterone 
administration might promote the conversion of energy to adipose tissue and exacerbate 
fat accumulation in older individuals. In addition, in the middle-aged rats although the 
serum leptin level was increased by testosterone administration, hypothalamic NPY 
mRNA expression was not affected. On the contrary, testosterone administration did not 
affect the serum leptin level in young rats. Thus, it is possible that testosterone induces 
hypothalamic leptin resistance, which might lead to the accumulation of fat in older 
individuals. Testosterone might disrupt the mechanisms that protect against adiposity and 
hyperphagia and could be a risk factor for excessive body weight and obesity, especially 
in older females. 
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Figure legends 
Fig. 1. 
Body weight (BW) change (% of initial BW) (A, B) and cumulative food intake (FI) 
(g/100 g BW) (C, D) in each group. Data are expressed as mean ± SEM values. Values 
with different letters (a-c) are significantly different (P <0.05). 
 
Fig. 2. 
Feed efficiency (BW gain/cumulative FI) (A); relative visceral, subcutaneous, and total 
fat weight (g/100 g BW) (B-D); and relative lean body mass (g/100 g BW) (E) in each 
group. Data are expressed as mean ± SEM values. Values with different letters (a-c) are 
significantly different (P <0.05). 
 
Fig. 3. 
Serum leptin level (A) and leptin mRNA level in visceral fat (B) in each group. Data are 
expressed as mean ± SEM values. Values with different letters (a-c) are significantly 
different (P <0.05). 
 
Fig. 4. 
Hypothalamic mRNA levels of the leptin receptor (OBRb) (A), the androgen receptor 
(AR) (B), neuropeptide Y (NPY) (C), pp-orexin (D), and proopiomelanocortin (POMC) 
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(E) in each group. Data are expressed as mean ± SEM values. Values with different letters 
(a, b) are significantly different (P <0.05). 
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Table 1    Primer sequences, product sizes and annealing temperature 
Primer Sequence Product size (bp) Annealing T (℃) 
AR forward CCC ATC GAC TAT TAC TTC CC 58 63 
AR reverse TTA CGA GCT CCC AGA GTC AT   
NPY forward GGG GCT GTG TGG ACT GAC CCT 148 66 
NPY reverse GAT GTA GTG TCG CAG AGC GGA G   
POMC forward CCT CAC CAC GGA AAG CA 104 66 
POMC reverse TCA AGG GCT GTT CAT CTC C   
OBRb forward GCA GCT ATG GTC TCA CTT CTT TTG 113 63 
OBRb reverse GTT CCC TGG GTG CTC TGA   
pporexin forward GCC GTC TCT ACG AAC TGT TG 303 60 
pporexin reverse CGA GGA GAG GGG AAA GTT AG   
leptin forward GGT CAC CGG TTT GGA CTT CAT 64 66 
leptin reverse CTG GTC CAT CTT GGA CAA ACT CA   
GAPDH forward ATG GCA CAG TCA AGG CTG AGA 64 70 
GAPDH reverse CGC TCC TG GAA GAT GGT GAT   
18S rRNA forward GAC GGA CCA GAG CGA AAG C <65 64 
18S rRNA reverse AAC CTC CGA CTT TCG TTC TTG A   
 
